Skip to main content

With 7.6% CAGR, Botulinum Toxin Market Size worth USD 5.68 Billion in 2028

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Players Covered in the Botulinum Toxin Market Research Report Are are AbbVie Inc. (Lake Bluff, U.S.), Ipsen Pharma (Paris, France), Revance Therapeutics, Inc. (California, U.S.), Merz Pharma (Frankfurt, Germany), Medytox (Cheongju-si, South Korea), USWM, LLC. (Kentucky, U.S.), GALDERMA (Lausanne, Switzerland), Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China), HUGEL, Inc. (Seoul, Republic of Korea) and other key market players.

Pune, India, Jan. 24, 2022 (GLOBE NEWSWIRE) — The global botulinum toxin market size was USD 3.20 billion in 2020. The market is projected to grow from USD 3.41 billion in 2021 to USD 5.68 billion in 2028 at a CAGR of 7.6% in the 2021-2028 period. This vital piece of information is published by Fortune Business Insights, in its report, titled, “Botulinum Toxin Market, 2021-2028.”

According to our analysts, the prime factors that drive the market growth are the rise in demand for cosmetic non-invasive surgical processes, novel product unveilings, surging flexible income, and alterations in compensation guidelines to afford botulinum injections.

Industry Developments:

July 2020: Teijin pharma gained marketing sanction for Xeomin in Japan. Tenjin Pharama and Merz Pharma collaboratively signed up for pharma sales based in Japan. Xeomin is essential for treating lower limb spasticity, and it will also be beneficial for treating post stroke spasticity patients.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/botulinum-toxin-market-100996


Drivers and Restraints:

Elevation in Demand of Minimally-invasive Cosmetic Methods to Spur Market Development

The increase in the demand for this method has also resulted in a substantial effect on the providers of dermatological provisions as well as other non-invasive techniques. Several pharmaceutical companies engaged in this field are progressively presenting products to satisfy the rising demand for botulinum toxin. This is expected to bolster the botulinum toxin market growth.

For instance, in June 2019, Huons Global, which is a South Korean company, declared the unveiling of Liztox, which is a botulinum neurotoxin based in Korea, for the treatment of reasonable to major glabellar wrinkles.

COVID-19 Impacts:

Rising Amount of Hospitals amid COVID-19 to Elevate Demand

The influence of COVID-19 is evidently noticeable in the healthcare sector as it is the major reason for this unparalleled global pandemic obstacle. The COVID-19 pandemic has adversely impacted the sales of botulinum toxin products globally owing to the declined demand in therapeutic as well as aesthetic usages. Moreover, stringent lockdowns norms, prohibition on elective processes, and hindrance in the supply chain are the principal detected aspects accountable for the deteriorated demand.


To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996


Regional Insights:

North America held the maximum botulinum toxin market shares and stood at USD 2.15 billion in 2020 owing to the hugely conscious and financially sturdy population along with a reasonably greater number of operative measures conducted in the region.

Europe held the second-largest share of the market, accredited to the rising inclination among people for performing Botox operations in major European nations and increasing spending on research and development in Europe.

Asia Pacific region is composed to perceive a greater demand for non-invasive aesthetic measures owing to the rising per person flexible income and increased disposition towards Asian nations for medical tourism.


Quick Buy –  Botulinum Toxin Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100996


Competitive Landscape:

Prime Companies to Execute Operative Strategies and Extend their Market Presence

Medical companies function importantly on the significance of the product and its demand in the market. Moreover, in order to elevate their market size & share, and to obtain a competitive edge, various leading players are involved in various strategic contracts in order to endorse their brand as well as amplify company sales.

List of Key Players Mentioned in the Botulinum Toxin Market Report:

  • AbbVie Inc. (Lake Bluff, U.S.)
  • Ipsen Pharma (Paris, France)
  • Revance Therapeutics, Inc. (California, U.S.)
  • Merz Pharma (Frankfurt, Germany)
  • Medytox (Cheongju-si, South Korea)
  • USWM, LLC. (Kentucky, U.S.)
  • GALDERMA (Lausanne, Switzerland)
  • Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China)
  • HUGEL, Inc. (Seoul, Republic of Korea)


Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Overview of the Number of Botulinum Toxin Injection Procedures by Key Countries
    • Overview of the Regulatory Scenario by Key Countries
    • Pricing Analysis
    • Overview of the Types of Botulinum Toxins
    • Pipeline Analysis
    • Key Industry Developments
    • Overview of Applications of Botulinum Toxin in Therapeutics and Recent Regulatory Approvals
    • Overview of the Reimbursement Scenario by Key Countries
    • Impact of COVID-19 on Global Botulinum Toxin Market
  • Global Botulinum Toxin Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Application
      • Therapeutics
        • Chronic Migraine
        • Spasticity
        • Overactive Bladder
        • Cervical Dystonia
        • Blepharospasm
        • Others
      • Aesthetics
    • Market Analysis, Insights and Forecast – By Type
      • Botulinum Toxin Type A
      • Botulinum Toxin Type B
    • Market Analysis, Insights and Forecast – By End User
      • Specialty & Dermatology Clinics
      • Hospitals & Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Geography
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/botulinum-toxin-market-100996


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/botulinum-toxin-market-9190

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.